Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NR3C4-targeted Nanoparticles
- Development stage
- Preclinical
- Lead developer
- Prosemble
- Modality
- Nanoparticles → Drug Delivery Systems
01
Overview
NR3C4-targeted Nanoparticles is a preclinical-stage targeted drug delivery system developed by Prosemble for the treatment of ovarian cancer. The platform utilizes nanoparticles engineered to specifically target the NR3C4 receptor, also known as the Androgen Receptor, which is expressed in certain ovarian tumors. By leveraging this targeting mechanism, the nanoparticles are designed to deliver therapeutic payloads directly to cancer cells, potentially enhancing treatment efficacy while minimizing systemic exposure and associated side effects. The development is currently in the preclinical phase, with the company exploring its utility in NR3C4-expressing malignancies.
- Other names
- Prosemble-NR3C4-nanoparticleProsemble-NR-3C4-nanoparticleProsemble-NR 3C4-nanoparticleNR3C4-targeted NanoparticlesNR-3C4-targeted NanoparticlesNR 3C4-targeted Nanoparticles
02
Targets
AR (Adrenergic receptors)
Beyond the preview
Go deeper on NR3C4-targeted Nanoparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NR3C4-targeted Nanoparticles.